CTOs on the Move

RCSB Protein Data Bank

www.rcsb.org

 
The Protein Data Bank (PDB) was established as the 1st open access digital data resource in all of biology and medicine. It is today a leading global resource for experimental data central to scientific discovery.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

RCSB Protein Data Bank raised $34.5M on 11/04/2019

Similar Companies

Glycomine

There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.

BioMotiv

BioMotiv is an accelerator company associated with The Harrington Project, a $340 million initiative centered at University Hospitals of Cleveland.

Organogenesis

Organogenesis Inc. is a Canton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rho

Welcome to a different kind of CRO. Bringing your product to market takes something different. At Rho, we`re experienced, creative problem-solvers who provide outstanding clinical research fueled by our unique team approach. Our dedication to collaboration makes your clinical trials and programs run smarter and more efficiently.

BioNTech

At BioNTech we understand that every cancer patient`s tumor is unique and therefore each patient`s treatment should be individualized. To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms. We were founded in 2008 in Mainz, Germany and have been driven to become the leading global biotechnology company for individualized cancer medicine. We have over 20 product candidates in development, 8 candidates in 9 ongoing clinical trials, treated over 250 patients across 17 tumor types and supported by more than 1100 employees. As we prove the value of our approach in the clinic, we continue to build a network of world-class corporate and scientific collaborators, manufacturing and team required to bring individualized treatments to patients worldwide.